Paysign Reports Q4 Revenue of $22.76M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy PAYS?
Reports Q4 revenue $22.76M, consensus $21.55M. "2025 was a standout year for Paysign, delivering record top- and bottom-line results," commented Mark Newcomer, President and CEO of Paysign. "We delivered continued, steady growth in our plasma compensation business and our differentiated solution for patient affordability enabled growth of more than 167%. We continued to scale our patient affordability platform, adding 55 net patient affordability programs during 2025, validating our focus on this business line and demonstrating our ability to generate a positive return on investment for pharmaceutical customers while improving patient access to copay funds. Patient affordability has become a primary driver of both growth and profitability. Demand for our differentiated solutions is strong and growing, reflecting the value of our technology, service model and real-time claims capabilities."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAYS
Wall Street analysts forecast PAYS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.760
Low
8.50
Averages
9.00
High
10.00
Current: 5.760
Low
8.50
Averages
9.00
High
10.00
About PAYS
Paysign, Inc. is a provider of prepaid card programs, patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. The Company’s payment solutions are utilized by its corporate customers to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. It markets its prepaid card solutions under its Paysign brand. Its end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. It operates on a payments platform with fintech capabilities that can be seamlessly integrated with its clients’ systems. It offers donor engagement app, which integrates seamlessly with existing donor management systems, delivering immediate value to plasma centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surge in Options Trading Volume for Paysign and ASTS
- Options Volume Surge for Paysign: Today, Paysign Inc's options volume reached 4,544 contracts, equivalent to approximately 454,400 shares, representing 89% of its average daily trading volume of 510,355 shares over the past month, indicating strong investor interest in the stock.
- High-Frequency Trading Insight: Notably, the $5 strike call option expiring on April 17, 2026, saw 2,713 contracts traded today, representing about 271,300 shares, suggesting market expectations for future price increases.
- ASTS Options Activity: Concurrently, AST SpaceMobile Inc recorded options trading volume of 114,469 contracts, approximately 11.4 million shares, which is 88.9% of its average daily trading volume of 12.9 million shares over the past month, reflecting sustained market interest in the company.
- Bullish Call Options Trend: Particularly, the $95 strike call option expiring on April 2, 2026, had 7,468 contracts traded today, representing around 746,800 shares, indicating optimistic sentiment among investors regarding ASTS's future performance.
See More
Paysign Stock Surges 35.81% Driven by Strong Earnings Report
- Stock Surge: Paysign's stock price surged 35.81% during Wednesday's trading, reaching $5.12 by 2:20 PM ET, reflecting strong market reaction to its financial performance, despite a roughly 1% decline in overall trading for 2026.
- Earnings Beat: The company reported fourth-quarter sales of $22.76 million, exceeding Wall Street's expectation of $21.55 million, with a year-over-year growth of nearly 26%, indicating enhanced competitiveness in the market.
- Optimistic Outlook: Management projects sales for 2026 to be between $106.5 million and $110.5 million, with achieving the midpoint indicating approximately 32.5% annual growth, showcasing strong momentum in both pharmaceuticals and plasma sectors.
- Profitability Improvement: Net income is expected to range from $13 million to $16 million, significantly up from $7.55 million last year, alongside a gross margin increase to 49.39%, which will further bolster market confidence in Paysign and potentially drive continued stock price appreciation.
See More
Paysign Q4 Earnings Beat Expectations, Stock Surges
- Earnings Surprise: Paysign reported Q4 sales of $22.76 million, exceeding Wall Street's expectation of $21.55 million, with a year-over-year growth of nearly 26%, showcasing the company's robust performance in the healthcare fintech sector and solidifying its market position.
- Optimistic Guidance: The company anticipates 2026 sales between $106.5 million and $110.5 million, with achieving the midpoint indicating approximately 32.5% annual growth, highlighting Paysign's dual growth potential in pharmaceuticals and plasma, which boosts investor confidence.
- Stock Surge: As of 2:20 p.m. ET, Paysign's stock surged by 35.8%, reflecting the market's positive reaction to its strong earnings and outlook, despite a roughly 1% decline in overall trading for 2026.
- Profitability Improvement: Projected net income is expected to range between $13 million and $16 million, significantly up from $7.55 million last year, and the increase in gross margins will further support profit growth, suggesting that the market may continue to reward Paysign with higher valuations.
See More
Paysign (PAYS) Q4 2025 Earnings Call Transcript
See More
Paysign Reports Exceptional Growth in 2025 Earnings Call
- Significant Revenue Growth: Paysign's total revenue for 2025 reached $82 million, a 40.5% year-over-year increase, with pharmaceutical revenue soaring 167.8% to $33.9 million, indicating strong performance in the patient affordability sector that is expected to drive future revenue growth.
- Improved Profitability: Net income surged 98% to $7.6 million, while adjusted EBITDA grew 107% to $19.9 million, with operating margins increasing by 723 basis points, demonstrating a critical inflection point in profitability and operational leverage that enhances investor confidence.
- Expansion in Patient Affordability: The patient affordability business saw annual revenue grow 168% to $33.9 million, with claims processed up approximately 79%, as the company added 55 programs over the year, bringing total active programs to 131, further solidifying partnerships with six of the top ten U.S. pharmaceutical manufacturers.
- Optimistic Future Outlook: Revenue guidance for 2026 is set between $106.5 million and $110.5 million, representing a 30% to 35% year-over-year growth, with net income projected to nearly double to between $13 million and $16 million, reflecting strong prospects driven by ongoing investments and growing market demand.
See More
Paysign Reports 45.8% Revenue Growth in Q4
- Earnings Overview: Paysign reported a profit of $1.362 million in Q4, with earnings per share remaining stable at $0.02, indicating consistent profitability despite a slight year-over-year decline.
- Revenue Surge: The company's revenue surged by 45.8% to $22.755 million from $15.606 million last year, showcasing strong business expansion and robust market demand.
- Year-over-Year Comparison: While profits saw a minor decrease, the significant revenue growth suggests enhanced competitiveness for Paysign, potentially attracting more investor interest in its future prospects.
- Market Outlook: With ongoing revenue growth, Paysign is positioned to further increase its market share and strengthen its leadership in the payment solutions sector.
See More
Surge in Options Trading Volume for Paysign and ASTS
- Options Volume Surge for Paysign: Today, Paysign Inc's options volume reached 4,544 contracts, equivalent to approximately 454,400 shares, representing 89% of its average daily trading volume of 510,355 shares over the past month, indicating strong investor interest in the stock.
- High-Frequency Trading Insight: Notably, the $5 strike call option expiring on April 17, 2026, saw 2,713 contracts traded today, representing about 271,300 shares, suggesting market expectations for future price increases.
- ASTS Options Activity: Concurrently, AST SpaceMobile Inc recorded options trading volume of 114,469 contracts, approximately 11.4 million shares, which is 88.9% of its average daily trading volume of 12.9 million shares over the past month, reflecting sustained market interest in the company.
- Bullish Call Options Trend: Particularly, the $95 strike call option expiring on April 2, 2026, had 7,468 contracts traded today, representing around 746,800 shares, indicating optimistic sentiment among investors regarding ASTS's future performance.
See More
Paysign Stock Surges 35.81% Driven by Strong Earnings Report
- Stock Surge: Paysign's stock price surged 35.81% during Wednesday's trading, reaching $5.12 by 2:20 PM ET, reflecting strong market reaction to its financial performance, despite a roughly 1% decline in overall trading for 2026.
- Earnings Beat: The company reported fourth-quarter sales of $22.76 million, exceeding Wall Street's expectation of $21.55 million, with a year-over-year growth of nearly 26%, indicating enhanced competitiveness in the market.
- Optimistic Outlook: Management projects sales for 2026 to be between $106.5 million and $110.5 million, with achieving the midpoint indicating approximately 32.5% annual growth, showcasing strong momentum in both pharmaceuticals and plasma sectors.
- Profitability Improvement: Net income is expected to range from $13 million to $16 million, significantly up from $7.55 million last year, alongside a gross margin increase to 49.39%, which will further bolster market confidence in Paysign and potentially drive continued stock price appreciation.
See More
Paysign Q4 Earnings Beat Expectations, Stock Surges
- Earnings Surprise: Paysign reported Q4 sales of $22.76 million, exceeding Wall Street's expectation of $21.55 million, with a year-over-year growth of nearly 26%, showcasing the company's robust performance in the healthcare fintech sector and solidifying its market position.
- Optimistic Guidance: The company anticipates 2026 sales between $106.5 million and $110.5 million, with achieving the midpoint indicating approximately 32.5% annual growth, highlighting Paysign's dual growth potential in pharmaceuticals and plasma, which boosts investor confidence.
- Stock Surge: As of 2:20 p.m. ET, Paysign's stock surged by 35.8%, reflecting the market's positive reaction to its strong earnings and outlook, despite a roughly 1% decline in overall trading for 2026.
- Profitability Improvement: Projected net income is expected to range between $13 million and $16 million, significantly up from $7.55 million last year, and the increase in gross margins will further support profit growth, suggesting that the market may continue to reward Paysign with higher valuations.
See More
Paysign (PAYS) Q4 2025 Earnings Call Transcript
See More
Paysign Reports Exceptional Growth in 2025 Earnings Call
- Significant Revenue Growth: Paysign's total revenue for 2025 reached $82 million, a 40.5% year-over-year increase, with pharmaceutical revenue soaring 167.8% to $33.9 million, indicating strong performance in the patient affordability sector that is expected to drive future revenue growth.
- Improved Profitability: Net income surged 98% to $7.6 million, while adjusted EBITDA grew 107% to $19.9 million, with operating margins increasing by 723 basis points, demonstrating a critical inflection point in profitability and operational leverage that enhances investor confidence.
- Expansion in Patient Affordability: The patient affordability business saw annual revenue grow 168% to $33.9 million, with claims processed up approximately 79%, as the company added 55 programs over the year, bringing total active programs to 131, further solidifying partnerships with six of the top ten U.S. pharmaceutical manufacturers.
- Optimistic Future Outlook: Revenue guidance for 2026 is set between $106.5 million and $110.5 million, representing a 30% to 35% year-over-year growth, with net income projected to nearly double to between $13 million and $16 million, reflecting strong prospects driven by ongoing investments and growing market demand.
See More
Paysign Reports 45.8% Revenue Growth in Q4
- Earnings Overview: Paysign reported a profit of $1.362 million in Q4, with earnings per share remaining stable at $0.02, indicating consistent profitability despite a slight year-over-year decline.
- Revenue Surge: The company's revenue surged by 45.8% to $22.755 million from $15.606 million last year, showcasing strong business expansion and robust market demand.
- Year-over-Year Comparison: While profits saw a minor decrease, the significant revenue growth suggests enhanced competitiveness for Paysign, potentially attracting more investor interest in its future prospects.
- Market Outlook: With ongoing revenue growth, Paysign is positioned to further increase its market share and strengthen its leadership in the payment solutions sector.
See More
